Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Orion Stalevo for Parkinson’s

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis/Orion's idiopathic Parkinson's disease therapy Stalevo (carbidopa, levodopa and entacapone) clears FDA June 11. The combination product adds entacapone (Novartis/Orion's Comtan) to the standard Parkinson's regimen of levodopa/carbidopa. Labeling says Stalevo can be used as a substitute for taking levodopa/carbidopa and Comtan separately. The firms have highlighted more convenient dosing as an advantage of the combo product (1Pharmaceutical Approvals Monthly Sept. 1, 2002, p. 59
Advertisement

Related Content

Novartis/Orion triple-combo Parkinson’s submission

Topics

Advertisement
UsernamePublicRestriction

Register

PS002303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel